MarketCap
Facebook
X
Telegram
Myomo Net Income | MYO
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Myomo
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -15.6 M | -6.2 M | -8.1 M | -10.7 M | -10.4 M | -11.6 M | -10.7 M | -10.3 M | -12.1 M | -3.62 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.62 M | -15.6 M | -9.93 M |
Quarterly Net Income Myomo
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.02 M | -3.01 M | -3.66 M | -4.63 M | -3.47 M | - | -966 K | -1.12 M | -3.84 M | - | -2.03 M | -1.01 M | -2.64 M | - | -2.83 M | -2.91 M | -2.81 M | - | -2.06 M | -2.62 M | -2.96 M | - | -2.78 M | -3.29 M | -3.8 M | - | -2.79 M | -2.57 M | -2.6 M | - | -2.65 M | -2.63 M | -2.35 M | - | -1.26 M | -7.38 M | -12.1 M | - | -1.02 M | -760 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -760 K | -12.1 M | -3.05 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Avanos Medical
AVNS
|
-72.9 M | $ 24.99 | - | $ 1.16 B |  USA |
 |
GBS
GBS
|
-12.4 M | - | -0.57 % | $ 7.12 M | USA |
 |
Second Sight Medical Products
EYES
|
26.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-19 M | - | - | $ 162 M |  France |
 |
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | USA |
 |
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | USA |
 |
BioSig Technologies
BSGM
|
-463 M | - | 37.08 % | $ 85.7 M | USA |
 |
ClearPoint Neuro
CLPT
|
-25.5 M | $ 15.39 | 1.32 % | $ 436 M | USA |
 |
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-6.09 M | - | - | $ 3.31 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
-517 M | $ 16.74 | 0.9 % | $ 1.28 B | USA |
 |
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | USA |
 |
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | USA |
 |
IRIDEX Corporation
IRIX
|
-4.44 M | $ 0.76 | 5.69 % | $ 12.9 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | USA |
 |
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | USA |
 |
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | USA |
 |
Integer Holdings Corporation
ITGR
|
103 M | $ 125.2 | 0.01 % | $ 4.35 B | USA |
 |
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-57.2 M | - | -10.19 % | $ 1.99 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 25.65 | 3.92 % | $ 602 M | USA |
 |
Eargo
EAR
|
-157 M | - | - | $ 10.2 M | USA |
 |
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | USA |
 |
LivaNova PLC
LIVN
|
-242 M | $ 78.74 | 0.68 % | $ 4.3 B |  Britain |
 |
LENSAR
LNSR
|
-34.3 M | $ 8.68 | 2.84 % | $ 104 M | USA |
 |
Electromed
ELMD
|
7.54 M | $ 39.45 | 0.69 % | $ 334 M | USA |
 |
Invacare Corporation
IVC
|
-20.6 M | - | - | $ 24.7 M | USA |
 |
Orthofix Medical
OFIX
|
-92.2 M | $ 10.01 | 2.54 % | $ 396 M |  Curacao |
 |
Outset Medical
OM
|
-81.7 M | $ 4.21 | 0.58 % | $ 64 K | USA |
 |
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
-8.2 M | $ 0.37 | 18.93 % | $ 23 M | USA |
 |
SmileDirectClub
SDC
|
-86.4 M | - | -53.45 % | $ 9.71 M | USA |
 |
Sientra
SIEN
|
-22 M | - | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
-55.7 M | - | - | $ 1.07 B | USA |
 |
Penumbra
PEN
|
178 M | $ 325.18 | 0.44 % | $ 12.7 B | USA |
 |
NanoVibronix
NAOV
|
-18.2 M | - | - | $ 1.08 M | USA |
 |
Surgalign Holdings
SRGA
|
-54.6 M | - | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
147 M | - | - | $ 12.3 B | USA |
 |
NuVasive
NUVA
|
40.4 M | - | - | $ 2.07 B | USA |
 |
Natus Medical Incorporated
NTUS
|
13.2 M | - | 1.94 % | $ 1.05 B | USA |
 |
Nevro Corp.
NVRO
|
-113 M | - | - | $ 217 M | USA |
 |
ThermoGenesis Holdings
THMO
|
-18.9 M | - | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
-62 M | - | 3.55 % | $ 7.96 M | USA |